Researchers in Belgium have identified a specific strain of bacteria naturally present in the human upper respiratory tract that may play a critical role in shielding the body from the debilitating effects of long COVID. The discovery suggests that the composition of our nasal and throat microbiomes—the complex communities of microorganisms living within us—could be a deciding factor in whether a patient recovers fully from a viral infection or descends into a chronic syndrome.
The study, conducted by an expert team at UCLouvain University in collaboration with the Saint-Luc University Hospital, points to a bacterium called Dolosigranulum pigrum as a key protector. When present in sufficient quantities, this microbe is strongly associated with a higher capacity for the body to recover from viral respiratory infections, potentially reducing the risk of developing post-COVID-19 syndrome and mitigating the severity of flu-like symptoms.
For the millions worldwide still struggling with “brain fog,” chronic fatigue, and respiratory issues, the finding shifts the conversation from treating the symptoms of long COVID to understanding the biological environment that prevents it. By focusing on bacteria that protect against long COVID, scientists are opening a new frontier in preventative medicine that leverages the body’s own microbial defenses.
The Role of the Respiratory Microbiome in Recovery
While much of the medical community’s attention has historically focused on the gut microbiome, this five-year project, which began in 2021, emphasizes the vital importance of the nasopharyngeal microbiota. The research team, including Dr. Leïla Belkhir, Professor Laure Elens, and scientist Patrice Cani, utilized advanced gene sequencing to analyze the microbial makeup of several patient groups: healthy individuals, those suffering from the flu, and patients with moderate to severe COVID-19.
By taking samples at the time of diagnosis and again three months later, the researchers were able to track how the microbial landscape shifted during the recovery process. To ensure accuracy, the team controlled for variables such as age, gender, the initial severity of the illness, and the apply of antibiotics.
The data revealed a consistent pattern: patients who maintained a healthy population of Dolosigranulum pigrum tended to fare better. This bacterium does not act alone; rather, it works in tandem with other beneficial microbes to stabilize the respiratory environment, making it harder for viral complications to take root and persist in the body.
The Antibiotic Paradox and Long-Term Vulnerability
One of the most significant takeaways from the study is the warning regarding the misuse of antibiotics. While these drugs are essential for treating bacterial infections, their broad-spectrum nature often results in “collateral damage,” wiping out beneficial bacteria like D. Pigrum along with the harmful ones.
The researchers found that a sharp decline in these protective bacteria—whether caused by a severe primary infection or the over-prescription of antibiotics—leaves the respiratory system vulnerable. This microbial depletion may create a biological vacuum that increases the likelihood of a prolonged illness or the onset of post-COVID symptoms.
This finding provides a scientific basis for more cautious antibiotic stewardship. In a clinical setting, the goal is increasingly to balance the need to kill pathogens with the necessity of preserving the commensal flora that supports long-term immune resilience.
The Burden of Post-COVID Syndrome
The urgency of this research is underscored by the ongoing public health crisis of long COVID. In Belgium alone, it is estimated that roughly 4% of the population—approximately 400,000 people—continue to suffer from lingering symptoms long after the initial virus has cleared. These symptoms often disrupt professional lives and diminish quality of life, creating a significant socioeconomic burden.
| Parameter | Detail |
|---|---|
| Key Microbe | Dolosigranulum pigrum |
| Study Duration | 5 Years (Started 2021) |
| Methodology | Gene sequencing of nasopharyngeal samples |
| Primary Outcome | Correlation between D. Pigrum and reduced long COVID risk |
| Publication | Microbiology Spectrum |
From Discovery to Prevention: Probiotic Nasal Sprays
The ultimate goal of the UCLouvain team is to translate these laboratory findings into a practical tool for public health. The researchers are currently working on the development of probiotic nasal sprays designed to introduce or bolster the presence of D. Pigrum and other beneficial bacteria in the nasal passages.
The vision is to create a preventative treatment that individuals could use before the peak of the respiratory illness season. By “priming” the respiratory microbiome, these sprays could potentially strengthen the body’s natural defenses, reducing both the risk of contracting severe infections and the likelihood of those infections evolving into chronic conditions.
This approach represents a paradigm shift in how we view respiratory health. Rather than relying solely on vaccines or antiviral medications after an infection has occurred, the focus moves toward maintaining a healthy microbial ecosystem to prevent the disease from becoming persistent.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next phase of this research will involve clinical trials to determine the efficacy and safety of these probiotic interventions. As the scientific community continues to map the respiratory microbiome, further updates on the development and regulatory approval of these nasal sprays are expected to emerge from the Belgian research teams.
Do you have experience with long COVID or thoughts on the use of probiotics for respiratory health? Share your thoughts in the comments or share this article with others who may discover it helpful.
